Tasimelteon: a selective and unique receptor binding profile.

Article Details

Citation

Lavedan C, Forsberg M, Gentile AJ

Tasimelteon: a selective and unique receptor binding profile.

Neuropharmacology. 2015 Apr;91:142-7. doi: 10.1016/j.neuropharm.2014.12.004. Epub 2014 Dec 19.

PubMed ID
25534555 [ View in PubMed
]
Abstract

Hetlioz((R)) (tasimelteon) is the first approved treatment in the United States for Non-24-Hour Sleep-Wake Disorder (Non-24). We present here data on the in vitro binding affinity of tasimelteon for both human melatonin receptors MT1 and MT2, as well as the extended screen of other receptors and enzymes. Results indicate that tasimelteon is a potent Dual Melatonin Receptor Agonist (DMRA) with 2.1-4.4 times greater affinity for the MT2 receptor believed to mediate circadian rhythm phase-shifting (Ki = 0.0692 nM and Ki = 0.17 nM in NIH-3T3 and CHO-K1 cells, respectively), than for the MT1 receptor (Ki = 0.304 nM and Ki = 0.35 nM, respectively). Tasimelteon was also shown to have no appreciable affinity for more than 160 other pharmacologically relevant receptors and several enzymes.

DrugBank Data that Cites this Article

Drugs
Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
TasimelteonMelatonin receptor type 1AProteinHumans
Yes
Agonist
Details
TasimelteonMelatonin receptor type 1BProteinHumans
Yes
Agonist
Details